Literature DB >> 9124860

Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study.

G V Doern1, A B Brueggemann, G Pierce, T Hogan, H P Holley, A Rauch.   

Abstract

Seven hundred twenty-three isolates of Moraxella catarrhalis obtained from outpatients with a variety of infections in 30 medical centers in the United States between 1 November 1994 and 30 April 1995 were characterized in a central laboratory. The overall rate of beta-lactamase production was 95.3%. When the National Committee for Clinical Laboratory Standards MIC interpretive breakpoints for Haemophilus influenzae were applied, percentages of strains found to be susceptible to selected oral antimicrobial agents were as follows: azithromycin, clarithromycin, and erythromycin, 100%; tetracycline and chloramphenicol, 100%; amoxicillin-clavulanate, 100%; cefixime, 99.3%; cefpodoxime, 99.0%; cefaclor, 99.4%; loracarbef, 99.0%; cefuroxime, 98.5%; cefprozil, 94.3%; and trimethoprim-sulfamethoxazole, 93.5%.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9124860      PMCID: PMC163641     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  Spectrum of disease due to Branhamella catarrhalis in children with particular reference to acute otitis media.

Authors:  C D Marchant
Journal:  Am J Med       Date:  1990-05-14       Impact factor: 4.965

2.  Analysis of the relationship between ampicillin resistance and beta-lactamase production in Branhamella catarrhalis.

Authors:  E E Stobberingh; H J van Eck; A W Houben; C P van Boven
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 3.  Branhamella catarrhalis--an emerging human pathogen.

Authors:  G V Doern
Journal:  Diagn Microbiol Infect Dis       Date:  1986-03       Impact factor: 2.803

4.  In vitro activities of 39 antimicrobial agents for Branhamella catarrhalis and comparison of results with different quantitative susceptibility test methods.

Authors:  G V Doern; T A Tubert
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

5.  beta-Lactamases of Branhamella catarrhalis and their inhibition by clavulanic acid.

Authors:  T Farmer; C Reading
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

6.  Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States.

Authors:  J H Jorgensen; G V Doern; L A Maher; A W Howell; J S Redding
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

7.  Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts.

Authors:  P Kirby; A Dunne; D H King; L Corey
Journal:  Am J Med       Date:  1990-05       Impact factor: 4.965

8.  Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis.

Authors:  B A Brown; R J Wallace; C W Flanagan; R W Wilson; J I Luman; S D Redditt
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

9.  In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.

Authors:  A L Barry; M A Pfaller; P C Fuchs; R R Packer
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

10.  Isoelectric focusing of beta-lactamases from sputum and middle ear isolates of Branhamella catarrhalis recovered in the United States.

Authors:  D R Nash; R J Wallace; V A Steingrube; P A Shurin
Journal:  Drugs       Date:  1986       Impact factor: 9.546

  10 in total
  16 in total

1.  Molecular characterization of the beta-lactamases from clinical isolates of Moraxella (Branhamella) catarrhalis obtained from 24 U.S. medical centers during 1994-1995 and 1997-1998.

Authors:  S S Richter; P L Winokur; A B Brueggemann; H K Huynh; P R Rhomberg; E M Wingert; G V Doern
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Production of BRO beta-lactamases and resistance to complement in European Moraxella catarrhalis isolates.

Authors:  Franz-Josef Schmitz; Andreas Beeck; Mirella Perdikouli; Mechthild Boos; Susanne Mayer; Sybille Scheuring; Karl Köhrer; Jan Verhoef; Ad C Fluit
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

3.  In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  A B Brueggemann; K C Kugler; G V Doern
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

4.  Moraxella (Branhamella) catarrhalis BRO beta-lactamase: a lipoprotein of gram-positive origin?

Authors:  H J Bootsma; P C Aerts; G Posthuma; T Harmsen; J Verhoef; H van Dijk; F R Mooi
Journal:  J Bacteriol       Date:  1999-08       Impact factor: 3.490

Review 5.  Moraxella catarrhalis: from emerging to established pathogen.

Authors:  Cees M Verduin; Cees Hol; André Fleer; Hans van Dijk; Alex van Belkum
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

6.  Moraxella catarrhalis outer membrane protein CD elicits antibodies that inhibit CD binding to human mucin and enhance pulmonary clearance of M. catarrhalis in a mouse model.

Authors:  Dai-Fang Liu; John C McMichael; Steven M Baker
Journal:  Infect Immun       Date:  2007-04-02       Impact factor: 3.441

7.  The transferrin binding protein B of Moraxella catarrhalis elicits bactericidal antibodies and is a potential vaccine antigen.

Authors:  L E Myers; Y P Yang; R P Du; Q Wang; R E Harkness; A B Schryvers; M H Klein; S M Loosmore
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

Review 8.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

9.  In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.

Authors:  Angela M Nilius; Linus L Shen; Dena Hensey-Rudloff; Laurel S Almer; Jill M Beyer; Darlene J Balli; Yingna Cai; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.

Authors:  George G Zhanel; Lorraine Palatnick; Kimberly A Nichol; Don E Low; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.